TMC1 and deafness: Prior gene therapy strategies that targeted TMC1 focused on gene replacement using conventional adeno-associated viral (AAV) vector serotypes to restore function in mouse models of recessive TMC1 deafness, DFNB7/1112, gene silencing using either AAV delivery of microRNAs13 or ribonucleotide protein complexes to deliver CRISPR/Cas914 to target dominant TMC1 mutations.